Bispecific molecules cross-linking ITIM and ITAM for therapy

Details Bispecific molecules cross-linking ITIM and ITAM for therapy Bispecific molecules cross-linking ITIM and ITAM for therapy

2006-10-10

2006-10-10

Wehbé, Anne Marie S. (Department: 1633)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Structurally-modified antibody, immunoglobulin, or fragment...

C424S143100, C424S144100, C424S173100, C530S387300, C530S387100, C530S388220, C530S388730

Reexamination Certificate

active

07118743

ABSTRACT:
The invention includes bispecific molecules capable of cross-linking ITAM and ITIM receptors on a cell in order to inhibit cell activation, as well as gene therapy approaches using nucleotides encoding such bispecific molecules for expression in vivo. One example of an ITAM/ITIM receptor pair is FcεRI and HM18, and another is FcεRI and FcγRII. Cross-linking of these receptors with a bispecific molecule of the invention would lead to inhibition of the release of allergic mediators and amelioration of the symptoms of allergic diseases. Other diseases can be ameliorated by cross-linking ITIM/ITAM receptor pairs.

REFERENCES:
patent: 4179337 (1979-12-01), Davis et al.
patent: 4495285 (1985-01-01), Shimizu et al.
patent: 4609546 (1986-09-01), Hiratani
patent: 4766106 (1988-08-01), Katre et al.
patent: 5225539 (1993-07-01), Winter
patent: 5530101 (1996-06-01), Queen et al.
patent: 5534254 (1996-07-01), Huston et al.
patent: 5693761 (1997-12-01), Queen et al.
patent: 5693762 (1997-12-01), Queen et al.
patent: 0 396 505 (1990-11-01), None
patent: 0 861 891 (1998-09-01), None
patent: WO 96/40788 (1996-12-01), None
patent: WO 98/09638 (1998-03-01), None
Arm et al. (1997) J. Immunol., vol. 159, 2342-2349.
Vossebeld et al. (1995) J. Biol. Chem., vol. 270, No. 18, 10671-10679.
Katz et al. (1997) J. Immunol., vol. 158, 5065-5070.
Karpovsky, B., Production of Target-Specific Effector Cells Using Hetero-Cross-Linked Aggregates Containing Anti-Target Cell and Anti-Fcγ Receptor Antibodies,J. Exp. Med.160:1686-1701 (1984).
Holgate, S. T., “The role of mast cells and basophils in inflammation”,Clin. Exp. Allergy,30(1):28-32 (2000).
Katz, H.R. et al., “Mouse mast cell gp49B1 contains two immunoreceptor tyrosine-based inhibition motifs and suppresses mast cell activation when colligated with the high affinity Fc receptor for IgE”,Proc. Nat. Acad. Sci. USA93:10809-10814 (1996).
Evans, M.J. et al., Rapid expression of an anti-human C5 chimeric Fab utilizing a vector that replicates in COS and 293 cellsJ.Immunol.,vol. 184, pp. 123-138 (1995).
Riechmann, L. et al., “Reshaping human antibodies for therapy”,Nature332:323-327 (1988).
Katz, H.R. et al., “Activation and Phorbol Ester-Stimulated Phosphorylation of a Plasma Membrane Glycoprotein Antigen Expressed on Mouse IL-3-Dependent Mast Cells and Serosal Mast Cells”,J.Immunol.,vol. 142(3): 919-926 (1989).
Low, N.M. et al., “Mimicking Somatic Hypermutation: Affinity Maturation of Antibodies Displayed on Bacteriophage Using a Bacterial Mutator Strain”,J. Mol. Biol.260:359-368 (1996).
Isakov, N., “ITIMs and ITAMs”,Immunol. Res.,16:85-100 (1997).
Huber, M. et al., “The src homology 2-containing inositol phosphatase (SHIP) is the gatekeeper of mast cell degranulation”,Proc. Nat. Acad. Sci. USA95:11330-11335 (1998).
Kirshenbaum, A.S. et al., “Effect of IL-3 and Stem Cell Factor on the Appearance of Human Basophils and Mast Cells from CD34+ Pluripotent Progenitor Cells”,J. Immunol.148(3):772-777 (1992).
Greenman, J. et al., “Characterization of a New Monoclonal Anti-Fcγ RII Antibody, AT10, and its Incorporation into a Bispecific F(ab')2Derivative for Recruitment of Cytotoxic Effectors”,Mol. Immunol.28(11):1243-1254 (1991).
Lardot, C. et al., “Expression of plasminogen activator inhibitors type-1 and type-2 in the mouse lung after administration of crystalline silica”,Eur. Respir. J.11:912-921 (1998).
Leung, D.Y.M., “Molecular Basis of Allergic Diseases”,Mol. Genet. And Metab.63:157-167 (1998).
Malbec, O. et al., “Fcε Receptor I-Associatedlyn-Dependent Phosphorylation of Fcγ Receptor IIB During Negative Regulation of Mast Cell Activation”,J. Immunol.160:1647-1658 (1998).
Ochi, H. et al., “T Helper Cell Type 2 Cytokine-mediated Comitogenic Responses and CCR3 Expression During Differentiation of Human Mast Cells In Vitro”,J. Exp. Med.190(2):267-280 (1999).
Roche, W. et al., “Subepithelial Fibrosis in the Bronchi of Asthmatics”,LancetMar. 11, 1989, pp. 520-524 (1989).
Renard, V. et al., “Transduction of cytotoxic signals in natural killer cells: a general model of fine tuning between activatory and inhibitory pathways in lymphocytes”,Immunol. Rev.155:205-221 (1997).
Sainte-Laudy, J. et al., “Analysis of anti-IgE and allegrgen induced human basophil activation by cytometry. Comparison with Histamine release”,Inflam. Res.47:401-408 (1998).
Silibar, C. et al. “Type β Transforming Growth Factors Promote Interleukin-3 (IL-3)-Dependent Differentiation of Human Basophils But Inhibit IL-3-Dependent Differentiation of Human Eosinophils”,Blood80(3):634-641 (1992).
Bléry, M et al., “Reconstituted Killer Cell Inhibitory Receptors for Major Histocompatibility Complex Class I Molecules Control Mast Cell Activation Induced via Immunoreceptor Tyrosine-based Activation Motifs”,J. Biol. Chem.272(14):8989-8996 (1997).
Daëron, M. et al., “Regulation of High-affinity IgE Receptor-mediated Mast Cell Activation by Murine Low affinity IgG Receptors”,J. Clin. Invest.95:577-585 (1995).
Vivier, E. et al., “Immunoreceptor tyrosine-based inhibition motifs”,Immunol. Today18(6):286-291 (1997).
Daëron, M., “Building up the family of ITIM-bearing negative coreceptors”,Immunol. Letters54:73-76 (1996).
Glennie, M.J. et al., “Preparation and Performance of Bispecific F(ab'γ)2Antibody Containing Thioether-Linked Fab' Fragments”,J. Immunol.139(7):2367-2375 (1987).
Grashoff, W.F.H. et al., “Chronic Obstructive Pulmonary Disease: Role of Bronchiolar Mast Cells and Macrophages”,Am. J. Pathol.151(6):1785-1790 (1997).
Daëron, M. et al., “Biology of Immunoreceptor Tyrosine-Based Inhibition Motif-Bearing Molecules”,In:Immunoreceptor Tyrosine Based Inhibition Motifs,Daëron ed., Chapter 1, Springer (1999).
DiBattista, J.A. et al., “Coordination Regulation of Matrix Metalloproteases and Tissue Inhibitor of Metalloproteinase Expression in Human Synovial Fibroblasts”,J. Rheumatol.22(Suppl 43):123128 (1995).
Fleming, T.J. et al., “Negative Regulation of FcεRI-mediated Degranualtion by CD81”,J. Exp. Med.186(8):1307-1314 (1997).

Affiliated with

Also associated with

Rating

Bispecific molecules cross-linking ITIM and ITAM for therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Bispecific molecules cross-linking ITIM and ITAM for therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bispecific molecules cross-linking ITIM and ITAM for therapy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3701103